Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Clinical Trial
Official title:
A Single-arm Study of Trastuzumab Deruxtecan (T-DXd) Monotherapy for Patients With HER2-expressing Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Received 2 or More Prior Regimens (DESTINY-Gastric06)
This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-expressing advanced gastric or GEJ adenocarcinoma who have received at least 2 prior regimens including a fluoropyrimidine agent and a platinum agent
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03407976 -
Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies
|
Phase 1 |